Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Biogen stock

Learn how to easily invest in Biogen stock.

Biogen
NASDAQ: BIIB-USD
About 33 hours ago

$257.68

-$1.25 (-0.48%)

Biogen is a drug manufacturers-general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Biogen employs 8,725 staff and has a trailing 12-month revenue of around $10 billion.

How to buy Biogen stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BIIB. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 in stock when you fund a new account within 30 days

Promoted for social trading

Finder Award

eToro


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for active trading

tastytrade


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Biogen stock price (NASDAQ: BIIB)

Use our graph to track the performance of BIIB stocks over time.

Biogen shares at a glance

Information last updated 2023-09-22.
Latest market close$257.68
52-week range$194.63 - $319.76
50-day moving average $266.74
200-day moving average $281.70
Wall St. target price$333.66
PE ratio 14.2035
Dividend yield $0 (0%)
Earnings per share (TTM) $18.23

Buy Biogen stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Ratings Available asset types Minimum deposit Signup bonus
SoFi Invest
Finder Rating: 4.6 / 5: ★★★★★

Finder Award
SoFi Invest
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
Get up to $1,000 in stock
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
eToro
Finder Rating: 4.2 / 5: ★★★★★

Finder Award
EXCLUSIVE
eToro
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
tastytrade
Finder Rating: 4.1 / 5: ★★★★★
tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures
$0
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Public.com
Finder Rating: 4 / 5: ★★★★★
Public.com
★★★★★
Stocks, ETFs, Cryptocurrency, Art, Treasury Bills, Collectibles
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
2.5% fee applies to all alternative asset transactions.
Robinhood
Finder Rating: 4.2 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4.9% interest on uninvested cash in your account with Robinhood Gold.
JPMorgan Self-Directed Investing
Finder Rating: 4 / 5: ★★★★★
JPMorgan Self-Directed Investing
★★★★★
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
$0
Get $50 - $700
when you open and fund an account with $5,000 - $250,000+
Pay no commissions on stocks, ETFs, mutual funds and options.
Wealthfront
Finder Rating: 4 / 5: ★★★★★
Wealthfront
★★★★★
Stocks, ETFs
$500
N/A
Wealthfront builds a free financial plan for the life you want and automate your investments at a low cost.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Biogen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biogen price performance over time

Historical closes compared with the close of $257.68 from 2023-09-22

1 week (2023-09-15) 1.13%
1 month (2023-08-24) -1.81%
3 months (2023-06-23) -9.43%
6 months (2023-03-24) -4.57%
1 year (2022-09-23) 30.29%
2 years (2021-09-20) -13.67%
3 years (2020-09-24) 270.04
5 years (2018-09-24) 347.02

Is Biogen stock undervalued or overvalued?

Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biogen financials

Revenue TTM $10 billion
Operating margin TTM 26.24%
Gross profit TTM $7.9 billion
Return on assets TTM 6.51%
Return on equity TTM 20.25%
Profit margin 26.72%
Book value $99.91
Market Capitalization $37.5 billion

TTM: trailing 12 months

Biogen share dividends

We're not expecting Biogen to pay a dividend over the next 12 months.

Have Biogen's shares ever split?

Biogen's shares were split on a 3:1 basis on 17 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.

Biogen share price volatility

Over the last 12 months, Biogen's shares have ranged in value from as little as $194.63 up to $319.76. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.1321. This would suggest that Biogen's shares are less volatile than average (for this exchange).

Biogen overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.

Frequently asked questions

What percentage of Biogen is owned by insiders or institutions?
Currently 0.679% of Biogen shares are held by insiders and 90.871% by institutions.
How many people work for Biogen?
Latest data suggests 8,725 work at Biogen.
When does the fiscal year end for Biogen?
Biogen's fiscal year ends in December.
Where is Biogen based?
Biogen's address is: 225 Binney Street, Cambridge, MA, United States, 02142
What is Biogen's ISIN number?
Biogen's international securities identification number is: US09062X1037
What is Biogen's CUSIP number?
Biogen's Committee on Uniform Securities Identification Procedures number is: 449370105

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site